Glenview Capital Bets More on This Healthcare Stock

Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Larry Robbins’ Glenview Capital has filed a 13D regarding a position of nearly 38 million shares in Health Management Associates (NYSE: HMA), a manager of hospitals primarily located in rural areas in the southern United States. Glenview has been a major shareholder in the company for some time; for example, at the beginning of this year, it owned about 35 million shares according to its 13F filing, making it one of the fund’s five largest holdings by market value -- but the filing of the 13D may signify that Robbins and his team plan to push for changes in the company’s strategy or Board of Directors.

We’d note that Glenview is also a major shareholder in many other hospital companies. Robbins himself is a former employee of billionaire Leon Cooperman’s Omega Advisors.

Net revenue was essentially flat last quarter compared to the first quarter of 2012, and with many of Health Management Associates’ costs (including salaries) rising, the company’s earnings dropped 39%. Adjusted earnings missed analyst expectations, as had occurred in the previous few quarters.

Currently, the market seems to be expecting Health Management Associates to improve from its current conditions: at a market capitalization of $2.9 billion, the stock currently trades at 19 times its trailing earnings. This has been in part due to a 57% increase in the stock price over the last year, easily outperforming the market. Wall Street analysts are also bullish, with consensus forecasts calling for $1.02 in earnings per share in 2014; that makes for a forward earnings multiple of 11.

That level is about even with where many other hospitals are trading at this time, though it is based on Health Management Associates hitting analyst targets. Of course, this move by Glenview might suggest that the fund has ideas for increasing shareholder value independent of operations. SAC Capital Advisors, managed by billionaire Steve Cohen, was buying the stock in the fourth quarter of 2012, and closed December with a total of 3.1 million shares in its portfolio (see Cohen’s stock picks).

We would compare Health Management Associates to Community Health Systems, HCA Holdings, LifePoint Hospitals (NASDAQ: LPNT), and Tenet Healthcare (NYSE: THC). The first two of these companies are priced at roughly the same level as Health Management Associates in terms of forward earnings estimates, with P/E multiples in the 10-11 range. Community Health Systems and HCA also get there on the basis of expectations of decent growth from the Street, even though each company reported flat revenue in its most recent quarter compared to the same period in the previous year. HCA actually saw its net income fall 36% over that time frame, and so as with Health Management Associates, we’d be skeptical that these two peers are actually value stocks.

LifePoint grew its revenue 9% in the first quarter of 2013 versus a year earlier, but it too experienced a sharp decline in earnings in percentage terms. With the company trading at 14 times consensus earnings for 2013, and its business not doing particularly well, we see no reason to prefer it to the other companies we’ve discussed. Tenet has more than doubled in price over the last year, bringing its forward P/E up to 14 as well. Revenue growth has been very limited, and we would be somewhat concerned that the stock is highly exposed to movements in the broader market with a beta of 2.4.

We don’t know what plans Glenview has for Health Management Associates, or even whether or not the fund actually has specific suggestions for management in mind (we would note that the stock rose 4% on May 7, likely at least in part a reaction to the news). Last quarter was not a good one for the company, and with it not seeming too attractive for its industry and with its valuation dependent on a considerable improvement in its earnings, we would advise against buying it at this time.

The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in the brand-new free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.

This article is written by Matt Doiron and edited by Meena Krishnamsetty. They don't have any position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!

blog comments powered by Disqus